Regorafenib impairs mitochondrial functions, activates AMP-activated protein kinase, induces autophagy, and causes rat hepatocyte necrosis

Toxicology

Volumn 327, Issue , 2015, Pages 10-21

  Weng, Zuquan ^a   Luo, Yong ^a   Yang, Xi ^a   Greenhaw, James J ^a   Li, Haibo ^a,c   Xie, Liming ^a,d   Mattes, William B ^b   Shi, Qiang ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b PharmPoint Consulting   (United States)

^c Nantong Center for Disease Control and Prevention   (China)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Hepatocyte; Hepatotoxicity; Mitochondrion; Necrosis; Rat; Regorafenib

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALCIUM; CHLOROQUINE; CYCLOSPORIN A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; OLIGOMYCIN; RAPAMYCIN; REGORAFENIB; TRIFLUOPERAZINE; CARBANILAMIDE DERIVATIVE; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHAGY; CALCIUM HOMEOSTASIS; ENZYME ACTIVATION; GLYCOLYSIS; LIVER CELL; LIVER MITOCHONDRION; LIVER NECROSIS; LIVER TOXICITY; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL PERMEABILITY; MITOCHONDRIAL RESPIRATION; MITOCHONDRION SWELLING; NONHUMAN; OXIDATIVE PHOSPHORYLATION UNCOUPLING; OXYGEN CONSUMPTION; RAT; ANIMAL; CYTOLOGY; DRUG EFFECTS; METABOLISM; NECROSIS; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

RATTUS;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; AUTOPHAGY; ENZYME ACTIVATION; HEPATOCYTES; MALE; MITOCHONDRIA, LIVER; NECROSIS; PHENYLUREA COMPOUNDS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84911092141     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2014.11.002     Document Type: Article

References (51)

1. Apostolova N., Gomez-Sucerquia L.J., Gortat A., Blas-Garcia A., Esplugues J.V. Compromising mitochondrial function with the antiretroviral drug efavirenz induces cell survival-promoting autophagy. Hepatology 2011, 54:1009-1019.
2. Brand M.D., Nicholls D.G. Assessing mitochondrial dysfunction in cells. Biochem. J. 2011, 435:297-312.
3. Bridges H.R., Jones A.J., Pollak M.N., Hirst J. Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem. J. 2014, 462:475-487.
4. Bruix J., Tak W.Y., Gasbarrini A., Santoro A., Colombo M., Lim H.Y., Mazzaferro V., Wiest R., Reig M., Wagner A., Bolondi L. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur. J. Cancer 2013, 49:3412-3419.
5. Cervinkova Z., Lotkova H., Krivakova P., Rousar T., Kucera O., Tichy L., Cervinka M., Drahota Z. Evaluation of mitochondrial function in isolated rat hepatocytes and mitochondria during oxidative stress. Altern. Lab. Anim. ATLA 2007, 35:353-361.
6. Chan F.K., Moriwaki K., De Rosa M.J. Detection of necrosis by release of lactate dehydrogenase activity. Methods Mol. Biol. 2013, 979:65-70.
7. Davis S.L., Eckhardt S.G., Messersmith W.A., Jimeno A. The development of regorafenib and its current and potential future role in cancer therapy. Drugs Today 2013, 49:105-115.
8. Ding W.X., Yin X.M. Analyzing macroautophagy in hepatocytes and the liver. Methods Enzymol. 2009, 453:397-416.
9. Dykens J.A., Will Y. The significance of mitochondrial toxicity testing in drug development. Drug Discov. Today 2007, 12:777-785.
10. Egan D.F., Shackelford D.B., Mihaylova M.M., Gelino S., Kohnz R.A., Mair W., Vasquez D.S., Joshi A., Gwinn D.M., Taylor R., Asara J.M., Fitzpatrick J., Dillin A., Viollet B., Kundu M., Hansen M., Shaw R.J. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 2011, 331:456-461.
11. EMA, 2013. Stivarga (regorafenib). http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm321378.htm.
12. FDA, 2012. Regorafenib.
13. FDA, 2012. Stivarga (regorafenib) tablets, Pharmacol. Rev. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203085Orig1s000PharmR.pdf.
14. Frezza C., Cipolat S., Scorrano L. Organelle isolation: functional mitochondria from mouse liver, muscle and cultured fibroblasts. Nat. Protoc. 2007, 2:287-295.
15. Gomez-Lechon M.J., Ponsoda X., O'Connor E., Donato T., Jover R., Castell J.V. Diclofenac induces apoptosis in hepatocytes. Toxicology In Vitro Int. J. 2003, 17:675-680. published in association with BIBRA.
16. Han D., Matsumaru K., Rettori D., Kaplowitz N. Usnic acid-induced necrosis of cultured mouse hepatocytes: inhibition of mitochondrial function and oxidative stress. Biochem. Pharmacol. 2004, 67:439-451.
17. Health-Canada, 2013. Stivarga. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2013_stivarga_157970-eng.php.
18. Horina J.H., Wirnsberger G.H., Kenner L., Holzer H., Krejs G.J. Increased susceptibility for CsA-induced hepatotoxicity in kidney graft recipients with chronic viral hepatitis C. Transplantation 1993, 56:1091-1094.
19. Imberti R., Nieminen A.L., Herman B., Lemasters J.J. Mitochondrial and glycolytic dysfunction in lethal injury to hepatocytes by t-butylhydroperoxide: protection by fructose, cyclosporin A and trifluoperazine. J. Pharmacol. Exp. Ther. 1993, 265:392-400.
20. Jones D.P., Lemasters J.J., Han D., Boelsterli U.A., Kaplowitz N. Mechanisms of pathogenesis in drug hepatotoxicity putting the stress on mitochondria. Mol. Interventions 2010, 10:98-111.
21. Kon K., Kim J.S., Jaeschke H., Lemasters J.J. Mitochondrial permeability transition in acetaminophen-induced necrosis and apoptosis of cultured mouse hepatocytes. Hepatology 2004, 40:1170-1179.
22. Leone A., Di Gennaro E., Bruzzese F., Avallone A., Budillon A. New perspective for an old antidiabetic drug: metformin as anticancer agent. Cancer Treat. Res. 2014, 159:355-376.
23. Lim C.T., Lolli F., Thomas J.D., Kola B., Korbonits M. Measurement of AMP-activated protein kinase activity and expression in response to ghrelin. Methods Enzymol. 2012, 514:271-287.
24. Malhi H., Gores G.J., Lemasters J.J. Apoptosis and necrosis in the liver: a tale of two deaths?. Hepatology 2006, 43:S31-44.
25. Malhi H., Guicciardi M.E., Gores G.J. Hepatocyte death: a clear and present danger. Physiol. Rev. 2010, 90:1165-1194.
26. Masubuchi Y., Yamada S., Horie T. Possible mechanism of hepatocyte injury induced by diphenylamine and its structurally related nonsteroidal anti-inflammatory drugs. J. Pharmacol. Exp. Ther. 2000, 292:982-987.
27. McGill M.R., Sharpe M.R., Williams C.D., Taha M., Curry S.C., Jaeschke H. The mechanism underlying acetaminophen-induced hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation. J. Clin. Invest. 2012, 122:1574-1583.
28. Meyers L.L., Beierschmitt W.P., Khairallah E.A., Cohen S.D. Acetaminophen-induced inhibition of hepatic mitochondrial respiration in mice. Toxicol. Appl. Pharmacol. 1988, 93:378-387.
29. Nagai H., Matsumaru K., Feng G., Kaplowitz N. Reduced glutathione depletion causes necrosis and sensitization to tumor necrosis factor-alpha-induced apoptosis in cultured mouse hepatocytes. Hepatology 2002, 36:55-64.
30. Ni H.M., Bockus A., Boggess N., Jaeschke H., Ding W.X. Activation of autophagy protects against acetaminophen-induced hepatotoxicity. Hepatology 2012, 55:222-232.
31. Nieminen A.L., Saylor A.K., Herman B., Lemasters J.J. ATP depletion rather than mitochondrial depolarization mediates hepatocyte killing after metabolic inhibition. Am. J. Physiol. 1994, 267:C67-74.
32. Okuda T., Norioka M., Shitara Y., Horie T. Multiple mechanisms underlying troglitazone-induced mitochondrial permeability transition. Toxicol. Appl. Pharmacol. 2010, 248:242-248.
33. Pernelle K., Le Guevel R., Glaise D., Stasio C.G., Le Charpentier T., Bouaita B., Corlu A., Guguen-Guillouzo C. Automated detection of hepatotoxic compounds in human hepatocytes using HepaRG cells and image-based analysis of mitochondrial dysfunction with JC-1 dye. Toxicol. Appl. Pharmacol. 2011, 254:256-266.
34. Pernicova I., Korbonits M. Metformin-mode of action and clinical implications for diabetes and cancer. Nat. Rev. Endocrinol. 2014, 10:143-156.
35. Pessayre D., Fromenty B., Berson A., Robin M.A., Letteron P., Moreau R., Mansouri A. Central role of mitochondria in drug-induced liver injury. Drug Metab. Rev. 2012, 44:34-87.
36. Petronilli V., Miotto G., Canton M., Brini M., Colonna R., Bernardi P., Di Lisa F. Transient and long-lasting openings of the mitochondrial permeability transition pore can be monitored directly in intact cells by changes in mitochondrial calcein fluorescence. Biophys. J. 1999, 76:725-734.
37. Porceddu M., Buron N., Roussel C., Labbe G., Fromenty B., Borgne-Sanchez A. Prediction of liver injury induced by chemicals in human with a multiparametric assay on isolated mouse liver mitochondria. Toxicol. Sci. Official J. Soc. Toxicol. 2012, 129:332-345.
38. Reid A.B., Kurten R.C., McCullough S.S., Brock R.W., Hinson J.A. Mechanisms of acetaminophen-induced hepatotoxicity: role of oxidative stress and mitochondrial permeability transition in freshly isolated mouse hepatocytes. J. Pharmacol. Exp. Ther. 2005, 312:509-516.
39. Rodriguez-Enriquez S., He L., Lemasters J.J. Role of mitochondrial permeability transition pores in mitochondrial autophagy. Int. J. Biochem. Cell Biol. 2004, 36:2463-2472.
40. Rodriguez R.J., Acosta D. Inhibition of mitochondrial function in isolated rate liver mitochondria by azole antifungals. J. Biochem. Toxicol. 1996, 11:127-131.
41. Saberi B., Ybanez M.D., Johnson H.S., Gaarde W.A., Han D., Kaplowitz N. Protein kinase C (PKC) participates in acetaminophen hepatotoxicity through c-jun-N-terminal kinase (JNK)-dependent and -independent signaling pathways. Hepatology 2014, 59:1543-1554.
42. Senior J.R. Why the threshold criteria should not be modified for detection of possibly serious drug-induced hepatotoxicity in special groups of trial subjects. Pharmacoepidemiol. Drug Safety 2013, 22:579-582.
43. Shackelford D.B., Shaw R.J. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat. Rev. Cancer 2009, 9:563-575.
44. Shah R.R., Morganroth J., Shah D.R. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Safety Int. J. Med. Toxicol. Drug Experience 2013, 36:491-503.
45. Shi Q., Yang X., Greenhaw J., Salminen W.F. Hepatic cytochrome P450s attenuate the cytotoxicity induced by leflunomide and its active metabolite A77 1726 in primary cultured rat hepatocytes. Toxicol. Sci. Official J. Soc. Toxicol. 2011, 122:579-586.
46. Sonko B.J., Schmitt T.C., Guo L., Shi Q., Boros L.G., Leakey J.E., Beger R.D. Assessment of usnic acid toxicity in rat primary hepatocytes using (1)(3)C isotopomer distribution analysis of lactate glutamate and glucose. Food Chem. Toxicol. Int. J. 2011, 49:2968-2974. published for the British Industrial Biological Research Association.
47. Starkov A.A., Bloch D.A., Chernyak B.V., Dedukhova V.I., Mansurova S.E., Severina I.I., Simonyan R.A., Vygodina T.V., Skulachev V.P. 6-Ketocholestanol is a recoupler for mitochondria, chromatophores and cytochrome oxidase proteoliposomes. Biochim. Biophys. Acta 1997, 1318:159-172.
48. Shi Q., Greenhaw J., Salminen W.F. Inhibition of cytochrome P450s enhances (+)-usnic acid cytotoxicity in primary cultured rat hepatocytes. Journal of Applied Toxicology:JAT 2014, 34:835-840.
49. Viollet B., Guigas B., Leclerc J., Hebrard S., Lantier L., Mounier R., Andreelli F., Foretz M. AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. Acta Physiol. 2009, 196:81-98.
50. Waldmeier P.C., Feldtrauer J.J., Qian T., Lemasters J.J. Inhibition of the mitochondrial permeability transition by the nonimmunosuppressive cyclosporin derivative NIM811. Mol. Pharmacol. 2002, 62:22-29.
51. Will Y., Dykens J.A., Nadanaciva S., Hirakawa B., Jamieson J., Marroquin L.D., Hynes J., Patyna S., Jessen B.A. Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicol. Sci. Official J. Soc. Toxicol. 2008, 106:153-161.